Comparison · NCT01954628-eb441734
AQX-1125 (200 mg) vs Placebo: The Number of Subjects With at Least One COPD Exacerbation.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. AQX-1125 (200 mg) vs Placebo: The Number of Subjects With at Least One COPD Exacerbation. Trial comparisons, record NCT01954628-eb441734. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01954628-eb441734
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.24 | 0.186 | 0.304 | wilson | |
| Risk in group 2 | 0.258 | 0.202 | 0.323 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0176 | -0.102 | 0.0672 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.932 | 0.662 | 1.31 | log | |
| Odds ratio, group 1 over group 2 | 0.91 | 0.578 | 1.43 | log | |
| Number needed to treat, for one fewer participant with the outcome on AQX-1125 (200 mg) than on Placebo | 56.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | AQX-1125 (200 mg) | 1 x AQX-1125 capsule daily | 48 | 200 | OG000 |
| Group 2 | Placebo | 1 x Placebo capsule daily | 51 | 198 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- The Number of Subjects With at Least One COPD Exacerbation.
- Description
- The number of subjects that presented with a COPD exacerbation during the 12 week treatment period.
- Time frame
- 12 weeks
- Population
- Full analysis set.
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of AQX-1125 in Unstable COPD
- NCT number
- NCT01954628
- Phases
- PHASE2
- Conditions
- COPD
- Interventions
- AQX-1125, Placebo
- Lead sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
- Results first posted
- 2017-06-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01954628?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01954628-eb441734